You have free access to this content

British Journal of Clinical Pharmacology

Cover image for Vol. 65 Issue s1

Special Issue: A Review of the Clinical Pharmacology of Maraviroc

April 2008

Volume 65, Issue Supplement s1

Pages 1–106

  1. A Review of the Clinical Pharmacology of Maraviroc Publication of this supplement was made possible through the support of Pfizer Inc.

    1. Top of page
    2. A Review of the Clinical Pharmacology of Maraviroc Publication of this supplement was made possible through the support of Pfizer Inc.
    3. Original articles
    1. Introduction

      You have free access to this content
      Introduction (pages 1–4)

      Marta Boffito and Samantha Abel

      Version of Record online: 10 MAR 2008 | DOI: 10.1111/j.1365-2125.2008.03131.x

  2. Original articles

    1. Top of page
    2. A Review of the Clinical Pharmacology of Maraviroc Publication of this supplement was made possible through the support of Pfizer Inc.
    3. Original articles
    1. You have free access to this content
      Assessment of the pharmacokinetics, safety and tolerability of maraviroc, a novel CCR5 antagonist, in healthy volunteers (pages 5–18)

      Samantha Abel, Elna Van Der Ryst, Maria C. Rosario, Caroline E. Ridgway, Christine G. Medhurst, Richard J. Taylor-Worth and Gary J. Muirhead

      Version of Record online: 10 MAR 2008 | DOI: 10.1111/j.1365-2125.2008.03130.x

      • image
      • image
      • image
      • image
    2. You have free access to this content
      Effect of maraviroc on the pharmacokinetics of midazolam, lamivudine/ zidovudine, and ethinyloestradiol/ levonorgestrel in healthy volunteers (pages 19–26)

      Samantha Abel, Deborah Russell, Lyndsey A. Whitlock, Caroline E. Ridgway and Gary J. Muirhead

      Version of Record online: 10 MAR 2008 | DOI: 10.1111/j.1365-2125.2008.03132.x

      • image
      • image
      • image
      • image
    3. You have free access to this content
      Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers (pages 27–37)

      Samantha Abel, Deborah Russell, Richard J. Taylor-Worth, Caroline E. Ridgway and Gary J. Muirhead

      Version of Record online: 10 MAR 2008 | DOI: 10.1111/j.1365-2125.2008.03133.x

      • image
      • image
      • image
      • image
      • image
    4. You have free access to this content
      Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers (pages 38–46)

      Samantha Abel, Timothy M. Jenkins, Lyndsey A. Whitlock, Caroline E. Ridgway and Gary J. Muirhead

      Version of Record online: 10 MAR 2008 | DOI: 10.1111/j.1365-2125.2008.03134.x

      • image
      • image
      • image
      • image
      • image
      • image
    5. You have free access to this content
      The effects of cotrimoxazole or tenofovir co-administration on the pharmacokinetics of maraviroc in healthy volunteers (pages 47–53)

      Samantha Abel, Deborah Russell, Lyndsey A. Whitlock, Caroline E. Ridgway and Gary J. Muirhead

      Version of Record online: 10 MAR 2008 | DOI: 10.1111/j.1365-2125.2008.03135.x

      • image
      • image
    6. You have free access to this content
    7. You have free access to this content
      Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects (pages 60–67)

      Samantha Abel, Deborah Russell, Lyndsey A. Whitlock, Caroline E. Ridgway, Angus N. R. Nedderman and Donald K. Walker

      Version of Record online: 10 MAR 2008 | DOI: 10.1111/j.1365-2125.2008.03137.x

      • image
      • image
      • image
      • image
      • image
    8. You have free access to this content
      Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects (pages 68–75)

      John D. Davis, Frances Hackman, Gary Layton, Tracy Higgins, David Sudworth and Georges Weissgerber

      Version of Record online: 10 MAR 2008 | DOI: 10.1111/j.1365-2125.2008.03138.x

      • image
      • image
      • image
      • image
    9. You have free access to this content
      A population pharmacokinetic meta-analysis of maraviroc in healthy volunteers and asymptomatic HIV-infected subjects (pages 76–85)

      Phylinda L. S. Chan, Barry Weatherley and Lynn McFadyen

      Version of Record online: 10 MAR 2008 | DOI: 10.1111/j.1365-2125.2008.03139.x

      • image
      • image
      • image
      • image
      • image
    10. You have free access to this content
      Population pharmacokinetic/ pharmacodynamic analysis of CCR5 receptor occupancy by maraviroc in healthy subjects and HIV-positive patients (pages 86–94)

      Maria C. Rosario, Philippe Jacqmin, Pat Dorr, Ian James, Timothy M. Jenkins, Samantha Abel and Elna Van Der Ryst

      Version of Record online: 10 MAR 2008 | DOI: 10.1111/j.1365-2125.2008.03140.x

      • image
      • image
      • image
      • image
      • image
    11. You have free access to this content
      A receptor theory-based semimechanistic PD model for the CCR5 noncompetitive antagonist maraviroc (pages 95–106)

      Philippe Jacqmin, Lynn McFadyen and Janet R. Wade

      Version of Record online: 10 MAR 2008 | DOI: 10.1111/j.1365-2125.2008.03141.x

      • image
      • image
      • image
      • image
      • image
      • image
      • image
      • image

SEARCH

SEARCH BY CITATION